5月19日，"追梦中华·感知四川"2025海外华文媒体四川采访行在蓉启动。来自加拿大、俄罗斯、西 班牙等15个国家和地区的15家海外华文媒体代表，以及两家涉侨中央媒体代表齐聚一堂，共同探索四川 魅力。 此次活动由中国侨联指导、四川省侨联主办，成都、内江、自贡、泸州等市（州）侨联具体承办， 为期7天的采访行程亮点纷呈，备受瞩目。 观察地区产业发展 前沿科技与产业集群共绽光芒 采访团首站来到了沃飞长空，这家明星企业作为中国低空经济领域的领军者，致力于全球低空智慧 交通飞行器的研发与商业化运营，其全球总部已于去年5月正式落地成都高新区。 "会飞的汽车何时落地？""新技术在未来城市发展中的应用场景有哪些？"……参观过程中，采访团 的问题一个接一个。在eVTOL航空器模拟驾驶舱内体验一番后，采访团成员纷纷表示，沉浸式的体验 让大家更直观、更真切地感受了四川在低空经济发展上的强劲动力。 不仅如此，采访团在自贡航空产业园再次见识到了四川通航领域产业集群的强大力量。在了解到园 区不仅有获批全国面积最大（1606平方公里）、高度最高（2400米以下）的"川协5号"低空改革试点空 域，还拥有全国唯一的两个通用机场等信息后，《北欧 ...

| SYMBOL $ | PRICE $ | CHANGE + | %CHANGE $ | LOW = | HIGH & | PREVIO | | --- | --- | --- | --- | --- | --- | --- | | TECHNOLOGY | 4,420.1 | -59.5 | -1.33 V | 4,391.32 | 4,451.79 | | | COMMUNICATION SVS | 345.33 | -3.44 | -0.99 V | 344.13 | 347.63 | | | CONS DISC | 1,688.65 | -15.56 | -0.91 V | 1,672.35 | 1,697.41 | | | INDUSTRIALS | 1,190.01 | -4.83 | -0.4 V | 1,179.81 | 1,194.31 | | | FINANCIALS | 831.14 | -3.25 | -0.39 V | 824.66 | 835.28 | | | HEALTH | 1,515.99 | -3.36 | -0.22 V | 1,507.6 | 1,519.33 | | ...

Economic Resilience - Guangdong's economy shows overall stability with industrial, consumption, and import-export indicators performing steadily despite external pressures [1][7] - The manufacturing sector grew by 4.1%, indicating a shift towards mid-to-high-end production [2][6] - Key industries such as computer, communication, and electronic equipment manufacturing saw a value-added growth of 7.1%, while electrical machinery and equipment manufacturing grew by 7.7% [2] Trade Performance - Guangdong's foreign trade import and export reached 2.96 trillion yuan, a year-on-year increase of 4.9%, outpacing the national growth rate of 2.5% [7] - Exports totaled 1.86 trillion yuan, growing by 2.1%, while imports increased by 10.1% to 1.1 trillion yuan [7][11] Consumer Demand - Social retail sales in Guangdong increased by 3.0% year-on-year, with a notable rise of 4.9% in April [11] - The implementation of policies such as the old-for-new consumption scheme has contributed to the recovery of consumer demand [15][16] Policy Support - The government has introduced various policies to support manufacturing and consumption, including tax incentives and streamlined regulations [20] - Specific retail categories, such as communication equipment and home appliances, saw significant sales growth, with some categories experiencing increases of over 60% [16][20] Technological Advancements - Guangdong's manufacturing sector is transitioning from traditional OEM models to building independent brands, enhancing product value and resilience against trade tensions [6][20] - The robotics industry in Guangdong is thriving, with products like AI-driven coffee machines being exported to over 60 countries [6]

文 | 银行螺丝钉 （转载请注明出处） 今天上午大盘一度上涨，到下午突然变成下跌。 截止到收盘，还在5星。 今天上午大盘一度上涨，到下午突然变成下跌。 大小盘股微跌，跌幅也差不多。 价值和成长风格也都下跌。 医药医疗等相对坚挺，略微上涨。 港股下午也下跌，不过到尾盘的时候反弹。 港股整体微涨。港股红利等微涨。 港股一季度财报发布也差不多了。 后面也会介绍下港股主流指数，一季度的盈利增长情况。 海外市场也出现了波动。 特朗普又开始搞事情，宣布要对欧洲等商品提高关税。 在消息宣布后，法股、德股指数一度下跌近3%。 美股开盘后也出现波动。 4月初全球市场因为关税事件，也出现过波动，导致全球股票市场一度下跌到4.1-4.2星。 随后5周全球股票市场反弹。 对美元来说，其实也承受不了太高的关税。 关税提高，有可能导致美股通货膨胀率提升；进而影响美联储降息放缓。 而美元债券规模庞大，较高的利率是比较沉重的负担。 高关税更多的是特朗普用来谈判的工具，而非根本目的，也不用太担心。 1. 有朋友问，今年港股医药涨的比较好，现在估值如何？ A股和港股，在医药指数分类上，有一些小的不同点。 （1）A股医药对应的是医药指数，例如中证 ...

Group 1 - The core viewpoint of the news is that Dachen Biochemical Technology (00809.HK) has entered into a strategic cooperation framework agreement with Hefei Hechen Biotechnology Co., focusing on the development of synthetic biology applications in the amino acid sector [1][2] - The strategic cooperation aims to leverage the strengths of both parties in synthetic biology, combining Dachen's experience in technology scaling, process optimization, and cost control with Hefei Hechen's expertise in gene design and metabolic pathway optimization [1][2] - A pilot platform for synthetic biology will be established at Dachen's Xinglongshan production base, which includes approximately 10,000 square meters of research and development facilities, supporting the industrialization of bio-based chemicals and medical materials [2] Group 2 - The unveiling of the pilot platform during the conference signifies a crucial step in bridging the gap between technological achievements and industrial application, facilitating breakthroughs in the bio-based chemical and medical materials sectors [2] - Hefei Hechen is focused on integrating synthetic biology with advanced delivery technologies, developing bio-based chemicals, specialty amino acids, and high-value active ingredients, as well as offering solutions for beauty products and functional food applications [2]

5月23日，截至港股收盘，恒生指数上涨0.24%，报23601.26点。福森药业（01652.HK）收报0.39港元/ 股，上涨30.0%，成交量430.9万股，成交额160.42万港元，振幅45.0%。 最近一个月来，福森药业累计涨幅11.11%，今年来累计跌幅62.5%，跑输恒生指数17.37%的涨幅。 财务数据显示，截至2024年12月31日，福森药业实现营业总收入3.26亿元，同比减少42.36%；归母净利 润-1.89亿元，同比减少420.39%；毛利率49.88%，资产负债率70.25%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，福森药业有限公司除提供核心产品双黄连类感冒药外,福森药业有限公司从事研发、生产及 销售多种用以治疗感冒及发热、心血管疾病及贫血的中成药及西药产品。福森药业有限公司对优质非处 方药及按现代剂型调配的处方中成药产品拥有专门知识。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.54倍，行业中值6倍。福森药业市盈 率-1.09倍， ...

央视网消息：民营经济促进法明确提出，国家鼓励、支持民营经济组织在推动科技创新、培育新质生产力、建设现代化产业体系中积极发挥作 用。2025年以来，融资、保险等金融要素资源，在投入民营企业的同时，产品设计也更加适配，为企业注入持续动能。 这家生物科技企业，主要从事细胞规模化生产及相关技术研发，是国家级专精特新"小巨人"企业。近期，企业计划升级核心技术，以覆盖更多 细胞品类，并探索全球化布局。这些业务的拓展都需要资金支持，但是这一次企业没有选择银行贷款，而是选择了金融资产投资公司的股权投 资。 区别于传统信贷，金融资产投资公司的股权投资，即AIC资金，不需要企业支付利息，可以降低企业的融资成本。同时，资金的投资周期较 长，能为这家企业提供持续的"耐心资本"支持。公司负责人表示，这笔股权投资的规模达到上亿元，目前相关业务已完成审批，即将签署协 议。 在AIC业务中，金融机构不再是传统的贷款提供方，而是从股东视角与企业共担风险，为企业提供综合的金融服务。 中国工商银行北京分行投资银行部副总经理刘洁介绍，他们不仅提供了账户结算、存贷款等基础保障服务，还为企业"量身定制"了一些创新金 融服务方案。此外，还会帮助企业对接更 ...

Market Overview - A-shares experienced slight fluctuations with major indices showing minor gains, including the Shanghai Composite Index rising for the fourth consecutive day [1] - The trading volume continues to shrink, indicating a potential decrease in market activity [1] Key Indices Performance - Shanghai Composite Index: 3,382.96 (+0.08%) - Shenzhen Component Index: 10,271.21 (+0.50%) - ChiNext Index: 2,055.44 (+0.48%) - Shanghai 50 Index: 2,738.01 (+0.16%) - CSI 300 Index: 3,925.58 (+0.30%) - STAR 50 Index: 993.56 (+0.29%) - North Exchange 50 Index: 1,410.71 (+1.58%) - CSI 1000 Index: 6,079.58 (+0.22%) [2] Pharmaceutical Sector - The pharmaceutical sector showed strong performance with significant gains in various sub-sectors, including AI healthcare and weight loss drugs, with some stocks reaching their daily limit [3] - Hengrui Medicine's H-shares debuted on the Hong Kong Stock Exchange, surging over 37% during trading, raising approximately HKD 9.9 billion, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [5] Innovation in Pharmaceuticals - China's pharmaceutical industry is rapidly developing, with exports reaching USD 26.632 billion in Q1 2025, a 4.39% increase year-on-year, while imports decreased by 4.42% to USD 20.456 billion [7] - The number of active innovative drugs developed by Chinese companies reached 3,575 by the end of 2024, ranking first globally, with domestic products accounting for 42% of approved innovative drugs [7] Automotive Industry - The automotive supply chain was active, with various segments such as passenger cars and automotive components showing strong gains [8] - The passenger car market saw sales of 6.872 million units from January to April, a 7.9% increase year-on-year, while the new energy vehicle market experienced a 35.7% increase with sales of 3.324 million units [10] Solid-State Battery Developments - The solid-state battery sector received positive news, with the China Automotive Engineering Society releasing standards for solid-state batteries, facilitating technological upgrades [11] - Companies like Funeng Technology and Guoxuan High-Tech are making significant advancements in solid-state battery development, with plans for commercial delivery of products by the end of 2025 [11]

| 15:00-15:30 | Building AI Virtual Cells (AIVC) with | | --- | --- | | | perturbation proteomics and active | | | learning 郭天南 西湖大学医学院和生命科学学院长聘副教授 | | 15:30-16:00 | Al for Science 行业探索和展望 | | | 冯小平 北京智谱华章科技有限公司 CIT创新中心负责人 | | 16:00-16:30 自然语言驱动,实验设计一步到位 | | | | Opentrons Al 让自动化触手可及 | | | 原非 Opentrons 全国销售总监 | | 16:30-17:00 | 深势科技 Al for Science | | | 医药研发数智化平台 | | | 李厦戎 深势科技 AI4S生命科学方案总监 | 90天 | 西湖大学医学院和生命科学学院长聘副教授 郭天南,西湖大学医学院、生命科学学院博士生导师、长聘 副教授,西湖大学蛋白质组复杂科学实验室负责人,西湖实 验室智能蛋白质组中心(WeCIP)主任,西湖大学未来产业 研究中心兼聘研究 ...

西风 发自 凹非寺 量子位 | 公众号 QbitAI 无特效疗法、无法根治的疾病，现在被「AI科学家」发现了潜在新疗法。 核 心流程完全由 AI驱动 ，人类研究员仅执行了实验室实验和最终论文撰写的那种。 最近非营利性组织Future House宣布了一个最新成果： 可以致盲的眼部疾病—— 干 性年龄相关 性黄斑变性 （dAMD） ，或许有救了。 他们用一个 多智能体系统 ，成功锁定 Ripasudil 这种已在日本获批用于临床治疗青光眼的ROCK抑制剂，对这种病具有潜在治疗效果。 团队咨询了多位有关此疾病领域的专家，均对这一发现的创新性和价值持认可态度。 重要的是，除实验室实际物理实验操作和最终手稿撰写外，论文形成所需的核心环节均由智能体完成，包括提出假设、实验设计、数据分析到 迭代优化的全流程。 甚至Agent还协助完成了论文图表的绘制。 整个研究仅耗时约10周 ，远短于研究团队手动完成所有计算机模拟环节的时间。 团队还特别说明，他们此前从未在其他文献中发现有人提出使用ROCK抑制剂治疗dAMD： 如果没有这些Agent，我们很难提出这一假设。 另外研究团队还表示， 将在下周开源代码和数据 。 这一成果公布 ...